Breast cancer can be categorised according to molecular subtype and stage of disease. Advanced breast cancer (aBC) describes both locally advanced and metastatic disease. Around 75% of aBC patients have hormone receptor-positive (HR+) tumours, with over 70% of these patients also having human epidermal growth factor receptor 2-negative (HER2−) tumours.1

Targeting hormone receptors via endocrine therapy has long been a mainstay of treatment for HR+/HER2− aBC. However, endocrine monotherapy typically only delays disease progression for around 1 year.2

The development of newer targeted therapies, such as CDK4/6 inhibitors, has widened options for treatment; in combination with endocrine therapy, they can improve clinical outcomes.2


CDK4/6, cyclin-dependent kinases 4/6; HR+/HER2−, hormone receptor-positive/human epidermal growth factor 2-negative. 


  1. El Sayed R, et al. Front Oncol 2019;9:510.
  2. Matutino A, et al. Curr Oncol 2018;25(Suppl 1):S131–S141.
HCP20-C006a August 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]